Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model

Medical Mycology

Volumn 45, Issue 3, 2007, Pages 221-224

  González, Gloria M ^a   Robledo, Efrén ^a   Saldívar, Donato ^b   González, Gerardo ^b   Bosques, Francisco ^b   Garza, Elvira ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Posaconazole; Therapeutic efficacy; Vaginal candidiasis

Indexed keywords

FLUCONAZOLE; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; VAGINA CANDIDIASIS;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; TRIAZOLES; VAGINA;

CANDIDA ALBICANS; MURINAE; MUS;

EID: 34248146052     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780601164298     Document Type: Article

References (14)

1. Sobel, JD. (1997) Vaginitis. N Engl J Med, 337, pp. 1896-1903.
2. Sobel, JD, Broker, D. and Stein, GE (1995) Single oral dose of fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole vaginitis Study Group. Am J Obstet Gynecol, 172, pp. 1263-1268.
3. Galgiani, JN and Lewis, ML. (1997) In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother, 41, pp. 180-183.
4. Cacciapuoti, A., Loebenberg, D. and Corcoran, E. (2000) In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother, 44, pp. 2017-2022.
5. Perfect, JR, Cox, GM, Dodge, RK and Schell, WA. (1996) In vitro and in vivo efficacies of the azole SCH 56592 against Cryptococcus neoformans. Antimicrob Agents Chemother, 40, pp. 1910-1913.
6. Kirkpatrick, WR, McAtee, RA and Fothergill, A. (2000) Efficiency of SCH 56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother, 44, pp. 780-782.
7. Connolly, P., Wheat, LJ and Schnizlein-Bick, C. (2000) Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother, 44, pp. 2604-2608.
8. Lutz, JE, Clemons, KV, Aristizabal, BH and Stevens, DA. (1997) Activity of the triazole SCH 56592 against disseminated murine coccidioidomicosis. Antimicrob Agents Chemother, 41, pp. 1558-1561.
9. González, GM, Tijerina, R. and Najvar, LK (2002) In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother, 46, pp. 1352-1356.
10. Sugar, AM and Liu, X-P. (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother, 40, pp. 1314-1316.
11. (2002) National Committee for Clinical Laboratory Standards, Wayne, PA
12. Calderon, L., Williams, R., Martinez, M., Clemons, KV and Stevens, DA. (2003) Genetic susceptibility to vaginal candidiasis. Med Mycol, 41, pp. 143-147.
13. Ryley, JF and McGregor, S. (1986) Quantification of vaginal Candida albicans infections in rodents. J Med Vet Mycol, 24, pp. 455-460.
14. Pfaller, MA, Bale, M. and Buschelman, B. (1995) Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol, 33, pp. 1104-1107.